Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III tri...

por Blagden, M, Hafer, J, Duerr, H, Hopp, M, Bosse, B
Publicado 2014

Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain

por Nadstawek, J, Leyendecker, P, Hopp, M, Ruckes, C, Wirz, S, Fleischer, W, Reimer, K
Publicado 2008

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

por Dupoiron, D., Stachowiak, A., Loewenstein, O., Ellery, A., Kremers, W., Bosse, B., Hopp, M.
Publicado 2017

Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, mu...

por Dupoiron, D., Stachowiak, A., Loewenstein, O., Ellery, A., Kremers, W., Bosse, B., Hopp, M.
Publicado 2017

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain

por Sandner-Kiesling, A, Leyendecker, P, Hopp, M, Tarau, L, Lejcko, J, Meissner, W, Sevcik, P, Hakl, M, Hrib, R, Uhl, R, Dürr, H, Reimer, K
Publicado 2010

The PerPAIN trial: a pilot randomized controlled trial of personalized treatment allocation for chronic musculoskeletal pain—a protocol

por Beiner, E., Baumeister, D., Buhai, D., Löffler, M., Löffler, A., Schick, A., Ader, L., Eich, W., Sirazitdinov, A., Malone, C., Hopp, M., Ruckes, C., Hesser, J., Reininghaus, U., Flor, H., Tesarz, J.
Publicado 2022